ReviewActa pharmaceutica Sinica. B2022
Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs.
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Towards the clinical translation of a novel autophagy inhibitor: Bisaminoquinoline derivative nanoparticles.Biomaterials · 2026Article
- A novel machine learning framework-based rapid screening of ionizable lipids in LNPs for highly-efficient mRNA expression.Acta pharmaceutica Sinica. B · 2026Article
- Assembly of Multilevel Nanoconstructs with Negatively Charged Lipid Envelope and Features of Its Interaction with Protein Corona.Nanomaterials (Basel, Switzerland) · 2026Article
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- β-Triketone-Based Ionizable Cationic Lipids Synthesized via Click Chemistry for siRNA Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Functional Reclassification of Lipid-Based Drug Delivery Systems and Advances in Formulation Strategies and Manufacturing Challenges.AAPS PharmSciTech · 2026Review
- From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.Asian journal of pharmaceutical sciences · 2026Review
- Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery.Acta pharmaceutica Sinica. B · 2026Review
- Lung-Targeting Interleukin-10 mRNA Lipid Nanoparticles Ameliorate Acute Lung Injury.bioRxiv : the preprint server for biology · 2026Article
- Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation.Frontiers in immunology · 2026Article
- Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026Review
- Non-viral gene delivery systems for osteoarthritis therapy.Biomaterials translational · 2026Review
- A Chemically Induced CRISPR/dCas13Journal of medicinal chemistry · 2025Article
- Dual CDK and MEK Inhibition potentiates CD8Journal of experimental & clinical cancer research : CR · 2025Article
- High-Throughput Strategies for Streamlining Lipid Nanoparticle Development Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.Bioactive materials · 2025Review
- Sulfonium lipid nanoparticles for intranasal mRNA delivery to lung epithelial and immune cells.Acta biomaterialia · 2025Article
- Novel Swelling-Lytic Cell Death Triggered by Cargo-Free Ionizable Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Lung-targeting lipid nanoparticle-mediated sparstolonin B delivery improves acute lung injury.Biomaterials science · 2025Article
- Emerging Strategies for Cargo Loading and Engineering of Extracellular Vesicles for Breast Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of bioactive agents, including the small molecule drugs, proteins and peptides, and nucleic acids. However, as the physicochemical properties of small- and macromolecular cargos can vary drastically, every LNP carrier system needs to be carefully tailored in order to deliver the cargo molecules in a safe and efficient manner. Our group applied the combinatorial library synthesis approach and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.